Abstract
Posttransplant renal dysfunction and cardiovascular risk factors can be a consequence of either direct or indirect adverse effects of current immunosuppressive regimes. Therefore, different safety profiles of immunosuppressive agents should be taken into account when evaluating their potential impact on long-term survival after heart transplantation. We focus on safety profiles of cyclosporine A (CsA), tacrolimus (Tac), mycophenolate mofetil (MMF) and rapamycin (Rapa) especially in terms of nephrotoxicity, glucose changes, hypertension and hyperlipidemia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
